Premium
Rituximab maintenance after autologous stem‐cell transplantation in patients with mantle cell lymphoma, final result of the LyMA trial conducted on behalf the LYSA group
Author(s) -
Le Gouill S.,
Thieblemont C.,
Oberic L.,
Moreau A.,
Bouabdallah K.,
Dartigeas C.,
Damaj G.,
Gastinne T.,
Ribrag V.,
Feugier P.,
Casasnovas O.,
Zerazhi H.,
Haioun C.,
Maisonneuve H.,
Van Den Neste E.,
Tournilhac O.,
Le Dû K.,
Morschhauser F.,
Cartron G.,
Fornecker L.,
Salles G.,
Tilly H.,
Lamy T.,
Gressin R.,
Hermine O.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_74
Subject(s) - mantle cell lymphoma , rituximab , medicine , autologous stem cell transplantation , oncology , transplantation , lymphoma
cycles). Conclusion: Obinutuzumab/ibrutinib combination has manageable safety profile and provides promising early clinical activity with high response rates in R/R MCL. Enrolment in step B (Obinutuzumab/ ibrutinib/Venetoclax) started in October 2016. Three patients has been included in the first cohort (Venetoclax = 400 mg). Data regarding step B will be updated in the final presentation.